Papers/PMID:28724644
The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials.
The American journal of clinical nutrition2017The record
2 findings drawn from this paper, on 1 compound across 2 endpoints.
What it reported
How to read these marksWhat moved
2 findings
magnesium(2+) — decreases diastolic blood pressure (setting unspecified)
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×2“The weighted overall effects indicated that the magnesium-supplementation group had a significantly greater reduction in both SBP (SMD: -0.20; 95% CI: -0.37, -0.03) and DBP (SMD: -0.27; 95% CI: -0.52, -0.03) than did the control group.”
Quoted verbatim from The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Participants
- 543
- Dose
- 365-450 mg/d elemental magnesium
- Population
- Individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases; 11 RCTs, all of which reported BP at baseline and end of trial
magnesium(2+) — decreases systolic blood pressure (setting unspecified)
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×2“The weighted overall effects indicated that the magnesium-supplementation group had a significantly greater reduction in both SBP (SMD: -0.20; 95% CI: -0.37, -0.03) and DBP (SMD: -0.27; 95% CI: -0.52, -0.03) than did the control group.”
Quoted verbatim from The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Participants
- 543
- Dose
- 365-450 mg/d elemental magnesium
- Population
- Individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases; 11 RCTs, all of which reported BP at baseline and end of trial